miRNA composition for detecting breast cancer brain metastases and kit with same

Abstract

The invention discloses a miRNA composition for detecting breast cancer brain metastases and a kit with same. The miRNA composition comprises miR-10b and one or more of miR-200a, miR-122, miR-21 and miR-181c. The kit comprises forward and reverse primers of the miRNA composition, forward and reverse primers of an external reference U6 RNA, a cerebrospinal fluid RNA extraction system, a reverse transcription reagent, a PCR amplification reagent and a cDNA mixed positive reference product. According to the miRNA composition, a group of miRNAs are adopted as novel breast cancer brain metastases markers, low specificity and low sensitivity caused by tumor heterogeneity are hard to overcome by using a single marker can be alleviated, prognosis effectiveness evaluation of a patient suffering from breast cancer can be effectively improved, and thus clinical treatment can be instructed. The miRNA composition is used for preparing a kit or a biological chip for prognosis inspection on breast cancer by using a fluorescent quantitative / digital PCR method, low specificity and low sensitivity caused by tumor heterogeneity can be avoided, the prognosis effectiveness evaluation of the patient suffering from breast cancer can be effectively improved, and thus clinical treatment can be instructed.

Description

technical field [0001] The invention belongs to the technical field of medical molecular biology, and in particular relates to a miRNA combination for detecting brain metastasis of breast cancer and a kit containing the combination. Background technique [0002] Breast cancer is the first malignant tumor in modern women, and its death rate ranks among the top five among all cancer deaths in women for a long time. The incidence of breast cancer is still gradually increasing all over the world. According to reports, by 2015, the incidence rate accounted for about 27% of all malignant tumors in women. Breast cancer is a cancer that is more prone to brain metastases, accounting for the second place in brain metastases, accounting for about 10% to 16%. The incidence of breast cancer in my country is also increasing at a growth rate of 3%-4%, which is higher than the average level of similar diseases in the world. According to reports, about 25%-40% of breast cancer patients may...

AI Technical Summary

Problems solved by technology

[0005] In view of the current low sensitivity of detection of breast cancer brain metastases

Among the existing patents, the patent with the application number CN200680036598.3 discloses the detection of dozens of miRNA combinations such as miR-10b, miR-21, and miR-122 in the cancer cells of the subject to determine breast cancer Prognosis, but it does not indicate whether the detected miRNA combination is related to brain metastasis, but only to determine whether the patient has the risk of breast cancer; the patent application number CN201680076769.4 discloses that by detecting miR-181c in blood, predicting cancer brain metastasis Metastasis, but with the in-depth development of cancer research, due to the existence of tumor heterogeneity, there are too many influencing factors to rely on a certain marker to diagnose the disease, which is not as valuable as combined diagnosis; in addition, it has been reported that miR- 181c, miR-21 is involved in tumor malignancy and metastasis, and the application number: CN201510090768.7 discloses that miR-21 can predict the early diagnosis of breast cancer, but for breast cancer brain metastasis, due to the abundant expression of miRNA in plasma / serum The degree is generally low, and the source is unknown, and the use of serum or plasma cannot accurately determine whether a patient has brain metastases

Images